Monotone Confounding, Monotone Treatment Selection and Monotone Treatment Response
Tyler J VanderWeele1, Zhichao Jiang2, Yasutaka Chiba3
1Departments of Epidemiology and biostatistics, Harvard School of Public Health, Boston, MA, USA, tvanderw@hsph.harvard.edu.
Abstract:
Manski (1997) and Manski and Pepper (2000) gave sharp bounds on causal effects under the assumptions of monotone treatment response (MTR) and monotone treatment selection (MTS). VanderWeele (2008) provided bounds for binary treatment under an assumption of monotone confounding (MC). We discuss the relation between MC and MTS and provide bounds under various combinations of these assumptions. We show that MC and MTS coincide for a binary treatment, but MC does not imply MTS for a treatment variable with more than two levels.
More Related Videos
04:09Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
Published on: October 10, 2018
06:55Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
Related Concept Videos
Dose Response Curve: Conventional Versus Nonmonotonic
Strategies for Assessing and Addressing Confounding
Confounding can be addressed at both the design phase of a study and through analytical methods after data...
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
Confounding in Epidemiological Studies
Parameters Affecting Nonlinear Elimination: Zero-Order Input, First-Order Absorption and Two-Compartment Model
When a drug is administered through a constant intravenous infusion and eliminated via nonlinear pharmacokinetics, it follows zero-order input. For example, oral drugs undergo first-order absorption upon administration and are eliminated through nonlinear pharmacokinetics.
In the case of subcutaneously administered drugs,...
Pharmacodynamic Models: Additive and Proportional Drug Effect Model
